全文获取类型
收费全文 | 139203篇 |
免费 | 44903篇 |
国内免费 | 211篇 |
专业分类
耳鼻咽喉 | 1993篇 |
儿科学 | 6512篇 |
妇产科学 | 2349篇 |
基础医学 | 24203篇 |
口腔科学 | 6211篇 |
临床医学 | 20941篇 |
内科学 | 35059篇 |
皮肤病学 | 8610篇 |
神经病学 | 19371篇 |
特种医学 | 3620篇 |
外国民族医学 | 4篇 |
外科学 | 19194篇 |
综合类 | 547篇 |
一般理论 | 87篇 |
预防医学 | 11632篇 |
眼科学 | 2080篇 |
药学 | 9185篇 |
2篇 | |
中国医学 | 1070篇 |
肿瘤学 | 11647篇 |
出版年
2024年 | 76篇 |
2023年 | 648篇 |
2022年 | 939篇 |
2021年 | 3079篇 |
2020年 | 6143篇 |
2019年 | 12330篇 |
2018年 | 11885篇 |
2017年 | 12718篇 |
2016年 | 13492篇 |
2015年 | 13439篇 |
2014年 | 13955篇 |
2013年 | 15512篇 |
2012年 | 9036篇 |
2011年 | 8977篇 |
2010年 | 11465篇 |
2009年 | 7619篇 |
2008年 | 6186篇 |
2007年 | 5162篇 |
2006年 | 5042篇 |
2005年 | 4568篇 |
2004年 | 4432篇 |
2003年 | 4083篇 |
2002年 | 3842篇 |
2001年 | 1257篇 |
2000年 | 1067篇 |
1999年 | 742篇 |
1998年 | 761篇 |
1997年 | 582篇 |
1996年 | 505篇 |
1995年 | 485篇 |
1994年 | 392篇 |
1993年 | 376篇 |
1992年 | 276篇 |
1991年 | 257篇 |
1990年 | 220篇 |
1989年 | 198篇 |
1988年 | 186篇 |
1987年 | 136篇 |
1986年 | 157篇 |
1985年 | 155篇 |
1984年 | 168篇 |
1983年 | 160篇 |
1982年 | 195篇 |
1981年 | 189篇 |
1980年 | 142篇 |
1979年 | 89篇 |
1978年 | 100篇 |
1977年 | 89篇 |
1976年 | 93篇 |
1975年 | 74篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
E. Wieczerzak E. Jankowska S. Rodziewicz‐Motowido A. Giedo J. giewka Z. Grzonka M. Abrahamson A. Grubb D. Brmme 《Chemical biology & drug design》2005,66(Z1):1-11
Abstract: We have designed and synthesized a new series of azapeptides which act as potential inhibitors of cathepsin B and/or cathepsin K. Their structures are based upon the inhibitory sites of natural cysteine protease inhibitors, cystatins. For the synthesized azapeptides, the equilibrium constants for dissociation of inhibitor–enzyme complex, Ki, were determined. Comparison of these values indicated that all of the azainhibitors act much stronger toward cathepsin B. Z‐Arg‐Leu‐His‐Agly‐Ile‐Val‐OMe ( 7 ) proved to be approximately 500 times more potent for cathepsin B than for cathepsin K. To be able to explain the obtained experimental values we used the molecular dynamics procedures to analyze the interactions between cathepsin B and compound 7 . We also determined the structure of the most potent and selective cathepsin B azainhibitor by means of NMR studies and theoretical calculations. In this report, we describe SAR studies of azapeptide inhibitors indicating the influence of the conformational flexibility of the examined compounds on inhibition of cathepsins B and K. 相似文献
42.
43.
44.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
45.
1 The internal anal sphincter (IAS) has a spontaneous tone and is the main contributor to the maintenance of faecal continence. The spontaneous resting tone exhibited by the sphincter can be modified by neurotransmitters from the autonomic and enteric nervous systems. 2 In this review, the influence of the sympathetic and parasympathetic nervous systems on IAS tone are discussed and the putative roles of nitric oxide, carbon monoxide, vasoactive intestinal peptide and adenosine triphosphate in non‐adrenergic non‐cholinergic transmission are considered. 3 Faecal incontinence is a common condition that places a heavy financial burden on the health service and severely affects patients’ quality of life. Resting anal pressure is reduced in patients with faecal incontinence and agents that increase sphincter tone tend to relieve symptoms. The results of clinical studies of the use of phenylephrine to treat faecal incontinence are reviewed. 4 It is concluded that the IAS is a potential target for drug development for the treatment of faecal incontinence. 相似文献
46.
47.
48.
Understanding the minimum clinically important difference: a review of concepts and methods. 总被引:2,自引:0,他引:2
Anne G Copay Brian R Subach Steven D Glassman David W Polly Thomas C Schuler 《The spine journal》2007,7(5):541-546
BACKGROUND CONTEXT: The effectiveness of spinal surgery as a treatment option is currently evaluated through the assessment of patient-reported outcomes (PROs). The minimum clinically important difference (MCID) represents the smallest improvement considered worthwhile by a patient. The concept of an MCID is offered as the new standard for determining effectiveness of a given treatment and describing patient satisfaction in reference to that treatment. PURPOSE: Our goal is to review the various definitions of MCID and the methods available to determine MCID. STUDY DESIGN: The primary means of determining the MCID for a specific treatment are divided into anchor-based and distribution-based methods. Each method is further subdivided and examined in detail. METHODS: The overall limitations of the MCID concept are first identified. The basic assumptions, statistical biases, and shortcomings of each method are examined in detail. RESULTS: Each method of determining the MCID has specific shortcomings. Three general limitations in the accurate determination of an MCID have been identified: the multiplicity of MCID determinations, the loss of the patient's perspective, and the relationship between pretreatment baseline and posttreatment change scores. CONCLUSIONS: An ideal means of determining the MCID for a given intervention is yet to be determined. It is possible to develop a useful method provided that the assumptions and methodology are initially declared. Our efforts toward the establishment of a MCID will rely on the establishment of specific external criteria based on the symptoms of the patient and treatment intervention being evaluated. 相似文献
49.
Acta Endoscopica - C’est un test de sélection. C’est un outil important de communication et d’information, c’est dire si elle doit être connue, comprise et bien... 相似文献
50.